These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 35172264)
1. Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis. Fu CC; Gao C; Zhang HH; Mao YQ; Lu JQ; Petritis B; Huang AS; Yang XG; Long YM; Huang RP Mult Scler Relat Disord; 2022 Mar; 59():103527. PubMed ID: 35172264 [TBL] [Abstract][Full Text] [Related]
3. Relationship between blood-brain permeability and antibodies against aquaporins in neuromyelitis optica spectrum disorders and multiple sclerosis patients. Jasiak-Zatońska M; Michalak S; Osztynowicz K; Kozubski W; Kalinowska-Łyszczarz A Neurol Neurochir Pol; 2022; 56(4):308-317. PubMed ID: 35029294 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia. Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527 [TBL] [Abstract][Full Text] [Related]
8. ABCB1 gene polymorphisms impact the effect of high-dose intravenous methylprednisolone therapy on optic neuritis associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder. Dai Y; Ni S; Wu F; Guo S; Zhao X; Wang J J Clin Pharm Ther; 2022 Sep; 47(9):1379-1387. PubMed ID: 35488449 [TBL] [Abstract][Full Text] [Related]
9. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J; J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741 [TBL] [Abstract][Full Text] [Related]
10. Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis. He M; Wu L; Huang D; Yau V; Yu S J Clin Neurosci; 2020 Sep; 79():108-112. PubMed ID: 33070876 [TBL] [Abstract][Full Text] [Related]
11. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186 [TBL] [Abstract][Full Text] [Related]
12. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911 [TBL] [Abstract][Full Text] [Related]
13. [Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders]. Krasnov VS; Totolyan NA; Nazarov VD; Mazing AV; Makshakov GS; Lapin SV; Evdoshenko EP; Skoromets AA Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):24-31. PubMed ID: 32844626 [TBL] [Abstract][Full Text] [Related]
14. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578 [TBL] [Abstract][Full Text] [Related]
15. Resolution of inflammation in neuromyelitis optica spectrum disorders. Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851 [TBL] [Abstract][Full Text] [Related]
16. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690 [TBL] [Abstract][Full Text] [Related]
17. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder. You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604 [TBL] [Abstract][Full Text] [Related]
18. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6. Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111 [TBL] [Abstract][Full Text] [Related]
19. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders. Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018 [TBL] [Abstract][Full Text] [Related]
20. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]